As a growing contract development and manufacturing organization (CDMO) for biologics and advanced therapies, Fujifilm Diosynth Biotechnologies recognized the criticality of flexibility and efficiency in manufacturing. Through a successful implementation, Fujifilm was able to not only recognize the benefits an integrated automation platform offers, but also the importance of working with an experienced partner.
While slower to adopt automation than other industries, the pharmaceutical industry continues to find ways to use it for improving quality and speed to market. Currently, there is a transformation taking place that will pave the way for even more changes in how the industry approaches drug manufacturing.
Lately this has become a popular question, with digital capabilities and automation emerging as a hot topic in the biomanufacturing community. With today’s complex manufacturing systems and processes, can a manufacturer afford to not have a centralized automation platform?
Integrating automation in a biomanufacturing environment successfully can become a daunting task without the right preparation and a clear implementation strategy. Through proper planning of your automation integration, you can eliminate costly errors and missteps and focus on developing efficient, future-proof automation strategies.
The need for process optimization, regulatory compliance, and supply chain improvements is driving investment in automation technologies across the life science industry. This article discusses the impact that multiproduct manufacturing facilities, single-use technologies, continuous manufacturing, and industry 4.0 will have on automation.
By applying remote monitoring solutions, advanced modeling, and optimization of manufacturing processes, Industry 4.0 offers improved process reliability and product quality through unlimited possibilities of connecting machines and data.